Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895467 | 0.82 | CDC7 (0.61) | HDAC1RAB9ACDC7P2RX7HDAC3 | |
| SCHEMBL10153571 | 0.81 | HDAC1 (0.52) | HDAC1CDC7P2RX7HDAC3HDAC2 | |
| SCHEMBL27432924 | 0.81 | HDAC1 (0.56) | HDAC1CDC7P2RX7HDAC3HDAC2 | |
| SCHEMBL5315811 | 0.81 | HDAC1 (0.52) | HDAC1MAPTCDC7P2RX7TSHR | |
| SCHEMBL25402344 | 0.78 | HDAC1 (0.57) | HDAC1MAPTTSHRCYP1A2CYP2C19 | |
| SCHEMBL2899293 | 0.78 | HDAC1 (0.60) | HDAC1CDC7HDAC3HDAC2HDAC10 | |
| SCHEMBL20592359 | 0.77 | HDAC1 (0.49) | HDAC1CDC7P2RX7TSHRCYP1A2 | |
| SCHEMBL24011415 | 0.77 | HDAC1 (0.48) | HDAC1CDC7P2RX7HDAC3HDAC2 | |
| SCHEMBL17086049 | 0.75 | CDC7 (0.54) | HDAC1CDC7P2RX7HDAC3HDAC2 | |
| SCHEMBL18381687 | 0.75 | CDC7 (0.54) | HDAC1CDC7P2RX7HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943004-B1 | RUTHENIUM-CATALYZED CYCLOADDITION OF ALKYNES AND ORGANIC AZIDES | SCRIPPS RESEARCH INST (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8372986-B2 | Ruthenium-catalyzed cycloaddition of alkynes and organic azides | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372986-B2 | Ruthenium-catalyzed cycloaddition of alkynes and organic azides | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100286405-A1 | Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-11 | — | — | US | disclosed |
| US-20100286405-A1 | Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-11 | — | — | US | disclosed |
| CN-101316640-A | Ruthenium-catalyzed cycloaddition of alkynes and organic azides | SCRIPPS RESEARCH INST (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1943004-A2 | RUTHENIUM-CATALYZED CYCLOADDITION OF ALKYNES AND ORGANIC AZIDES | The Scripps Research Institute (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007041451-A2 | RUTHENIUM-CATALYZED CYCLOADDITION OF ALKYNES AND ORGANIC AZIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | HDAC1 1096/4885NPC1 648/4885MAPT 3578/4885 |
| US-20100286405-A1 | Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides | CBR3, AOC3, CYB5R3 | HDAC1 2070/4885NPC1 4201/4885MAPT 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.